About this trial
This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke
Eligibility criteria
Qualifiers
15≤ NIHSS score ≤32;
3<GCS score ≤12;
CT hypodensity area >1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.
Disqualifiers
Hemorrhagic transformation of PH2 type prior to randomization;
Brain herniation or decompressive craniectomy performed before randomization;
Hemodynamic instability refractory to medical correction (systolic blood pressure <70 mmHg or diastolic blood pressure <50 mmHg) or decompensated heart failure (NYHA Class III or IV);
Severe hepatic impairment (defined as ALT >2 times the upper limit of normal or AST >2 times the upper limit of normal) and renal impairment (defined as serum creatinine >1.5 times the upper limit of normal or estimated glomerular filtration rate [eGFR] <50 mL/min);
Trial design
Treatments tested in this trial
- Hemoadsorption
Treatment groups
Sponsors and collaborators
First Affiliated Hospital of Wannan Medical College
Lead sponsor
Anqing Municipal Hospital
Collaborator
Beijing Tiantan Hospital
Collaborator
Gansu Provincial Central Hospital
Collaborator
Baotou Central Hospital
Collaborator
The NO.1 People's Hospital of Shizuishan
Collaborator
Fuyang people's hospital
Collaborator
Second People's Hospital of Hefei City
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
THE SECOND PEOPLE'S HOSPITAL, WUHU
Collaborator